Newsroom



News

PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.



  • May 24, 2015
  • Noninvasive findings reduce catheterisation need in suspected PAH
  • (News Medical) Research shows that a risk score based on noninvasive measures can identify left heart failure (LHF) in a “substantial percentage” of patients with suspected pulmonary arterial hypertension (PAH), reducing the need for right heart catheterisation (RHC).
  •   
  • Meta-analysis supports ambrisentan efficacy
  • (News Medical) A meta-analysis supports the efficacy of ambrisentan in patients with pulmonary arterial hypertension (PAH).
  •   
  • May 23, 2015
  • Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
  • (7th Space) Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using sildenafil and tadalafil, for multi-drug-resistant PAH.
  •   
  • New Data Show Need for Improved Monitoring for Pulmonary Hypertension Following Pulmonary Embolism
  • (Virtual Press Office) Results from a retrospective cohort study presented today at the American Thoracic Society (ATS) 2015 International Conference in Denver found that the incidence of pulmonary hypertension (PH) among patients who experienced pulmonary embolism (PE) was twice as high as expected based on previous studies, and that many patients do not receive necessary follow-up tests.
  •   
  • May 22, 2015
  • Celsion Corporation Announces TheraSilence Technology Effective in Model of Potential Severe Occlusive PAH Treatment
  • (Pulmonary Hypertension News) Celsion Corporation, an oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies, recently announced an abstract publication in the Journal of Controlled Release. The abstract summarizes results from a preclinical trial which confirmed the effective delivery of RNA to lung cells — findings that have implications in the treatment of Severe Occlusive PAH.Celsion Corporation, an oncology company focused on developing a portfolio of innovative cancer treatments, including ...
  •   
  • Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost
  • (Pulmonary Circulation) n patients with pulmonary hypertension and heart failure with preserved ejection fraction, inhaled iloprost resulted in acute reduction of pulmonary arterial pressure and pulmonary vascular resistance. Further evaluation of iloprost in this subset of patients is warranted.
  •   
  • Arginine metabolic endotypes in pulmonary arterial hypertension
  • (Pulmonary Circulation) Compared with healthy controls, PAH patients had a tendency toward increased arginine clearance and ornithine flux but no difference in arginine and citrulline flux, de novo arginine synthesis, or NO synthesis. Arginine-to-ADMA ratio was increased in PAH patients. Two endotypes of patients with low and high arginase activity were identified; compared with the low-arginase group, the patients with high arginase had increased arginine flux, slower NO synthesis, and lower plasma concentrations of ADMA. These results demonstrate that increased breakdown of arginine by arginase occurs in PAH and affects NO synthesis. Furthermore, there is no compensatory increase in de novo arginine synthesis to overcome this increased utilization of arginine by arginase.
  •   
  • Impact of diabetes in patients with pulmonary hypertension
  • (Pulmonary Circulation) Despite similar management, survival was markedly worse and remained so after statistical adjustment. In summary, diabetic patients referred for assessment of PH were more likely to have pulmonary venous disease than nondiabetic patients with PH, with hemodynamics suggesting greater right-sided diastolic dysfunction. The markedly worse survival in these patients merits further study.
  •   
  • May 21, 2015
  • ATS: Combo Tx Cuts Admissions in PAH
  • (MedPage Today) Among 253 patients treated with the combination, 8% had a PAH-related admission, compared with 18% of 247 receiving monotherapy with one of these agents (HR 0.372, 95% CI 0.217-0.639, P=0.0002), according to Jean-Luc Vachiery, MD, director of the pulmonary vascular diseases unit of Erasme Hospital in Brussels.
  •   
  • Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension
  • (Pulmonary Circulation) Nebulized iloprost delivered via the I-neb AAD system reduced mPAP and PVR and increased CI from baseline in a heterogeneous group of patients with PH and in the subset with iPAH. In patients with iPAH, inhalation of 2.5 µg or 5.0 µg iloprost resulted in broadly similar peak iloprost plasma levels.
  •   
  • May 20, 2015
  • Association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-?) gene and systemic sclerosis.
  • (Pubmed) The multifunctional nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) has potent anti-fibrotic effects, and its expression and activity are impaired in patients with systemic sclerosis (SSc). We investigated PPAR-γ gene (PPARG) single nucleotide polymorphisms (SNPs) associated with SSc.

    A PPARG variant is associated with susceptibility to SSc, consistent with a role of PPAR-γ in the pathogenesis of SSc.-
  •   
  • Mitral Valve Surgery Identified As Potential Treatment For PAH Secondary to Mitral Valve Disease
  • (Pulmonary Hypertension News) In a recent study entitled “An excellent result of surgical treatment in patients with severe pulmonary arterial hypertension following mitral valve disease,” authors analyzed recent outcomes and mortality rates for patients with pulmonary arterial hypertension who underwent mitral valve surgery. They observed a significant decrease in the number of deaths and suggest that mitral valve surgery is an effective treatment and relatively safe in this group of patients. The study was published in the Journal of Cardiothoracic Surgery.
  •   
  • May 19, 2015
  • ATS 2015 Denver
  • (American Toracic Society 2015 program)

    Read through the Abstracts here.
     

  •   
  • May 18, 2015
  • Red Blood Cell Distribution Width (RDW) can predict Vasolilator Response
  • (PubMed) RDW independently predicts responsiveness of acute pulmonary vasodilator testing in patients with IPAH. RDW is associated with disease severity and all-cause death.
  •   
  • May 17, 2015
  • Inhaler Ban Boosts Costs for People With Asthma
  • (Medscape) A 2008 ban on chlorofluorocarbons (CFCs) has ended up being particularly costly for people with asthma.
  •   
  • Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at American Thoracic Society (ATS) Conference 2015
  • (Yahoo Finance) Actelion Ltd (ATLN.VX) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi®), will be shared during an oral presentation at the American Thoracic Society (ATS) Conference in Denver, Colorado, USA.
  •   
  • May 16, 2015
  • You May Be Getting Up to Pee At Night Because of Sleep Apnea
  • (Huffington Post) Just like clockwork, it's time to get up and pee again. If it seems like the bane of getting a continuous night of sleep in middle age and beyond, it may not have to be. Learn a surprising reason why you may have to wake to urinate at night and how improvement can occur without seeing a urologist, but a sleep specialist instead.
  •   
  • Harpoon Medical Enrolls Initial Three Patients in Early Feasibility Study of Its Repair System for off-Pump, Minimally Invasive Treatment of Mitral Valve Regurgitation
  • (Business Wire) Harpoon Medical, a medical device company focused on minimally invasive mitral valve repair, announced today that it has enrolled the initial three patients in an Early Feasibility Study of its repair system for the minimally invasive, beating-heart treatment of MR. The initial first-in-human procedures were performed at the Department of Cardiovascular Surgery and Transplantology, Jagiellonian University John Paul II Hospital, by the team of Krzysztof Bartus, Jerzy Sadowski, Boguslaw Kapelak, James Gammie, and Andrzej Gackowski.
  •   
  • May 15, 2015
  • Patients with scleroderma at highest risk for pulmonary arterial hypertension
  • (Healio) CHICAGO - Risks for pulmonary hypertension and pulmonary arterial hypertension among patients with scleroderma were discussed by Harrison Farber, MD, at the American College of Rheumatology State-of-the-Art Clinical Symposium, here.
  •   
  • May 14, 2015
  • Pediatric Pulmonary Hypertension Registry Receives NIH Funding
  • (Pulmonary Hypertension News) National Heart, Lung and Blood Institute has awarded a grant to two investigators from the Children’s Hospital of Philadelphia (CHOP) for their work creating an informatics registry for pediatric patients who suffer from pulmonary hypertension (PH). The institute from the National Institutes of Health (NIH) recognized nine pediatric centers, which are members of the Pediatric Pulmonary Hypertension Network (PPHNet).
  •   
  • May 13, 2015
  • SteadyMed seeks orphan drug designation from FDA for Trevyent to treat PAH
  • (Pharmaceutical Business Review) US-based pharmaceutical firm SteadyMed Therapeutics has submitted an application to the US Food and Drug Administration (FDA) seeking orphan drug designation for its lead drug product candidate, Trevyent, to treat pulmonary arterial hypertension (PAH), a rare, progressive, life-threatening disease.

  •   
  • May 12, 2015
  • An excellent result of surgical treatment in patients with severe pulmonary arterial hypertension following mitral valve disease
  • (7th Science) Objective:  Observe the efficacy of surgical treatment in patients with severe pulmonary arterial hypertension caused by mitral valve disease. 
  •   
  • May 11, 2015
  • Bellerophon Therapeutics Creates PH-Focused Scientific Advisory Board For INOpulse Programs
  • (Pulmonary Hypertension News) Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, recently announced the formation of a Scientific Advisory Board (SAB) for its INOpulse technology that includes internationally recognized experts in the field of pulmonary hypertension (PH). The SAB will work closely with Bellerophon’s medical team while the firm prepares to further the advancement of its proprietary inhaled nitric oxide drug-device combination technology across a wide range of several indications for those affected by PH.
  •   
  • May 10, 2015
  • Researchers Developing Registry for Pediatric Pulmonary Hypertension
  • (The Childrens Hospital of Philadelphia) While pulmonary hypertension (PH) is a relatively rare problem in pediatrics, the frequency of the diagnosis and PH-related hospitalizations are rising. PH complicates a number of different disease processes, including congenital heart disease, chronic lung disease of prematurity, and genetic disorders. In other cases, the cause of PH may be unknown.
  •   
  • Bosentan in pulmonary hypertension secondary to unilateral absence of a pulmonary artery
  • (International Journal of Cardiology) Unilateral absence of a pulmonary artery is a rare congenital anomaly caused by the failure of the sixth aortic arch to connect with the pulmonary trunk during the embryologic development, while it is often associated with other cardiovascular abnormalities such as tetralogy of Fallot, septal defects, right aortic arch, and persistence of ductus arteriosus, and usually discovered in the pediatric age. It can be incidentally discovered in adult patients complaining of recurrent episodes of respiratory infections with or without exertional dyspnea and always complicated with hemoptysis, recurrent pulmonary infections or pulmonary hypertension.
  •   
  • May 9, 2015
  • Ascendis Pharma Releases Results of Phase 1 Study of PAH Therapy TransCon Treprostinil
  • (Pulmonary Hypertension News) Ascendis Pharma A/S, a clinical stage biotechnology company focused on creating drug candidates by improving existing drugs, recently announced results from its Phase 1 single ascending dose trial of TransCon Treprostinil, which produced a dose-dependent increase in plasma treprostinil levels. However, results from the study showed that the tolerability of treprostinil injection-site did not meet the criteria described in the target product profile.
  •   
  • What is new about Rio?
  • (ERS Journal) This issue of the European Respiratory Journal includes the results of three different studies of riociguat, a soluble guanylate cyclase stimulator, for the treatment of pulmonary hypertension. As the first drug in a novel class for the treatment of pulmonary hypertension, riociguat has raised hopes of an expanded drug armamentarium against the still incurable diseases of pulmonary arterial hypertension (PAH) and surgically inaccessible (or persistent post-operative) chronic thromboembolic pulmonary hypertension (CTEPH). Two of these studies are long-term extension studies from pivotal phase III trials: CHEST-1 (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1) and PATENT-1 (Pulmonary Arterial Hypertension Soluble Guanylate Cyclase–Stimulator Trial 1). The third study (PATENT PLUS) studied the safety and efficacy of the combination of riociguat and the phosphodiesterase (PDE)-5 inhibitor, sildenafil.
  •   
  • May 8, 2015
  • SteadyMed Submits Application for Orphan Drug Designation for Trevyent(R) For Pulmonary Arterial Hypertension
  • (Globe Newswire) SteadyMed Ltd. (Nasdaq:STDY) a specialty pharmaceutical company, today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its lead drug product candidate, Trevyent, for the treatment of pulmonary arterial hypertension (PAH). The FDA has acknowledged receipt of the application and will notify SteadyMed when the review process is completed. If granted, Orphan Drug Designation in the U.S. would qualify Trevyent for various development incentives such as tax credits, waiver of New Drug Application (NDA) submission fees, possibility for a priority review upon filing of its NDA submission, and potentially a 7-year period of marketing exclusivity after NDA approval is granted.
  •   
  • Genetic and phenotypic differentiation of an Andean intermediate altitude population.
  • (PubMed) Highland populations living permanently under hypobaric hypoxia have been subject of extensive research because of the relevance of their physiological adaptations for the understanding of human health and disease. In this context, what is considered high altitude is a matter of interpretation and while the adaptive processes at high altitude (above 3000 m) are well documented, the effects of moderate altitude (below 3000 m) on the phenotype are less well established. In this study, we compare physiological and anthropometric characteristics as well as genetic variations in two Andean populations: the Calchaquíes (2300 m) and neighboring Collas (3500 m). We compare their phenotype and genotype to the sea-level Wichí population...
  •   
  • May 7, 2015
  • Iptakalim attenuates hypoxia-induced pulmonary arterial hypertension in rats by endothelial function protection.
  • (Spandidos Publications) In this trial Iptakalim significantly attenuated the increase in mean pulmonary artery pressure, RVSP, right ventricle to left ventricle plus septum ratio and small pulmonary artery wall remodeling in hypoxia?induced PAH rats. Iptakalim also prevented an increase in IL?1β and a decrease in IL?10 in the peripheral blood and lung tissue, and alleviated inflammatory cell infiltration in hypoxia?induced PAH rats. Furthermore, iptakalim enhanced PECAM?1 and eNOS expression and prevented the endothelial cell injury induced by hypoxic stimuli. Iptakalim suppressed the pulmonary arteriole and systemic inflammatory responses and protected against the endothelial damage associated with the upregulation of PECAM?1 and eNOS, suggesting that iptakalim may represent a potential therapeutic agent for PAH.
  •   
  • May 6, 2015
  • 3D Human Lung Tissue Cultures Used to Test COPD Therapeutics
  • (Lung Disease News) In a recent study entitled “Preclinical validation and imaging of Wnt-induced repair in human 3D lung tissue cultures,” researchers developed ex vivo 3D human lung tissue cultures (3D-LTCs) to determine the benefits of therapeutics for chronic obstructive pulmonary disease (COPD). They tested for the first time the potential for Wnt/β-catenin activating compounds to induce lung repair in patient-derived 3D-LTCs. The study was published in the European Respiratory Journal.
  •   
  • May 4, 2015
  • PhaseBio Announces Promising Pre-Clinical Results for PB1046 in Models of Duchenne Muscular Dystrophy
  • (Globe Newswire) PB1046 is based on Vasoactive Intestinal Peptide (VIP), a naturally occurring neuropeptide that exerts its physiological effects through activation of G protein-coupled receptors – VPAC1 and VPAC2 that are widely distributed throughout the cardiovascular, pulmonary and immune systems. The extremely short in vivo half-life of VIP has precluded its therapeutic use. Utilizing Elastin-Like Polypeptide (ELP) technology, PhaseBio has overcome these limitations, demonstrating prolonged circulatory drug exposure in humans. PB1046 has been shown to be highly effective in pre-clinical studies of hypertension, pulmonary arterial hypertension and in multiple heart failure models, with positive cardiac inotropic (contractility) and lusitropic (relaxation) effects without an increase in myocardial oxygen demand. Furthermore, proof of concept was established on the safety, pharmacokinetics and hemodynamic activity measured directly by means of changes in blood pressure as a surrogate following single subcutaneous and intravenous administration of PB1046 in two clinical trials conducted in volunteers with essential hypertension. - See more at: http://globenewswire.com/news-release/2015/04/22/726983/10130090/en/PhaseBio-Announces-Promising-Pre-Clinical-Results-for-PB1046-in-Models-of-Duchenne-Muscular-Dystrophy.html#sthash.RVLPxdcL.dpuf
  •   
  • May 3, 2015
  • Long-Term Selexipag Phase 3 Clinical Trial Results For PAH Recently Presented
  • (Pulmonary Hypertension News) Long-term results for the GRIPHON trial are in. According to a presentation made at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions, selexipag (otherwise known as Uptravi® from Actelion) effectively treats patients with pulmonary arterial hypertension. Patients saw an enhanced outcome of disease when treated with selexipag rather than placebo and had a 40% lower risk for morbidity and mortality events than patients receiving placebo treatment.
  •   
  • Latest Clinical Study Finds Ventripoint VMS(TM) Offers Consistent and Accurate Results Regardless of Examiner
  • (Digital Journal) "This clinical study demonstrates that the VMS analysis of the right heart is reproducible between operators", stated Jim Bodtke, Vice President of Clinical Affairs for Ventripoint. "This means that the cardiologist can trust previous test results regardless of the examiner, so long as the echocardiagram was analyzed using the VMS. Further, the study determined that results produced by VMS were more accurate and reproducible than Fractional-Area Change, which is one of the methods of estimating right-heart function recommended by the ASE guidelines." The imaging guidelines, published by the American Society of Echocardiography (ASE) in the Journal of the ASE, are written by experts in the field of echocardiography and cardiology, and provide a recommended standard of care.
  •   
  • May 2, 2015
  • Serodus Files Patent Application in UK To Begin Pulmonary Hypertension Therapy Development
  • (Pulmonary Hypertension News) Serodus ASA recently announced that the company has filed a provisional patent application with the United Kingdom patent office for its experimental SER100 therapy, which will begin development for treatment of Pulmonary Hypertension.
  •   
  • Pulmonary arterial hypertension market expected to reach USD 5.19 billion globally in 2020 outlined in new market research report
  • (WhaTech) Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, sGC Stimulators and Selexipag) - GlobThe global PAH market was valued at USD 4.04 billion in 2013 and is expected to grow at a CAGR of 2.3% from 2014 to 2020, to reach an estimated value of USD 5.19 billion in 2020.
  •   
  • May 1, 2015
  • Early Mortality Still a Factor in Systemic Sclerosis
  • (MedPage Today) MANCHESTER, England -- Despite recent advances in treatment, age at death among inpatients with systemic sclerosis has not improved, according to an analysis of 57 centers in the Irish Hospital Inpatient Enquiry system.
  •   
  • April 30, 2015
  • Ascendis Pharma Reveals Results of Phase 1 Study of Pulmonary Arterial Hypertension Therapy TransCon Treprostinil
  • (Pulmonary Hypertension News) Ascendis Pharma A/S, a clinical stage biotechnology company focused on creating drug candidates by improving existing drugs, recently announced results from its Phase 1 single ascending dose trial of TransCon Treprostinil, which produced a dose-dependent increase in plasma treprostinil levels. However, results from the study showed that the tolerability of treprostinil injection-site did not meet the criteria described in the target product profile.
  •   
  • April 29, 2015
  • Multidisciplinary Approach Key to Management of Pregnant Pulmonary Hypertension Patients
  • (Pulmonary Hypertension News) Findings from a recent study published in the Annals of Cardiac Anaesthesia determined that a multidisciplinary approach is key to the successful management of pregnant patients with Pulmonary Hypertension (PH). According to the study, secondary PH results in higher morbidity and mortality, and in particular the older the age, the higher the maternal morbidity and mortality.
  •   
  • April 28, 2015
  • Researchers Find That Estrogen Receptor Alpha is Linked to Pulmonary Hypertension Development
  • (Pulmonary Hypertension News) Researchers at the University of Glasgow and Glasgow Caledonian University in the United Kingdom published in the journal Cardiovascular Research findings revealing that that a specific receptor of the hormone estrogen is involved in the development of pulmonary hypertension. The findings may offer new insights into why PH disproportionately affects women. The study is entitled “Oestrogen receptor alpha in pulmonary hypertension.”
  •   
  • April 27, 2015
  • Pulmonary Hypertension‚Äôs Link To Hepatic Cirrhosis Explored in New Study
  • (Pulmonary Hypertension News) According to a new paper, “Pulmonary hypertension and hepatic cirrhosis,” published in the Spanish-language journal, Revista Clinica Espanola, pulmonary hypertension (PH) occurs frequently in people with hepatic cirrhosis. There are various ways in which hepatic cirrhosis can be caused by PH, but the most common occurrence is something called portopulmonary syndrome–or PPH for short.
  •   

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives